⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7967516 | 0.78 | MEN1 (0.32) | — | |
| SCHEMBL96573 | 0.72 | MEN1 (0.50) | — | |
| SCHEMBL7537126 | 0.69 | TSHR (0.30) | — | |
| SCHEMBL12633675 | 0.69 | — | — | |
| SCHEMBL2970306 | 0.67 | MEN1 (0.46) | — | |
| SCHEMBL277501 | 0.67 | MEN1 (0.44) | — | |
| SCHEMBL1133203 | 0.67 | MEN1 (0.62) | — | |
| Iodomethane SCHEMBL7443879 | 0.67 | MEN1 (0.38) | — | |
| SCHEMBL7967923 | 0.67 | — | — | |
| SCHEMBL28203844 | 0.65 | MEN1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-10064879-B2 | Method for treating depression and/or depression status with substituted quinoxaline compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-04 | — | — | US | disclosed |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| EP-2753329-B1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS MELK INHIBITORS | ONCOTHERAPY SCIENCE INC (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9345709-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20160058757-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMA CO LTD (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20150328225-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-0711760-A1 | METHOD OF ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
| WO-1996010562-A1 | 1-ACYL-4-ALIPHATYLAMINOPIPERIDINE COMPOUNDS | NOVARTIS AG (CH) | 1996-04-11 | — | — | WO | disclosed |
| EP-0641321-A1 | SUBSTITUTED ISOINDOLONES | BASF Aktiengesellschaft (DE) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993024456-A1 | SUBSTITUTED ISOINDOLONES | BASF AKTIENGESELLSCHAFT (DE) | 1993-12-09 | — | — | WO | disclosed |
| EP-0227795-A4 | METHOD FOR PERFORMING NUCLEIC ACID HYBRIDIZATION ASSAYS. | AMGEN (US) | 1989-01-26 | — | — | EP | disclosed |
| EP-0224578-A4 | COMPOSITIONS AND METHODS FOR FUNCTIONALIZING NUCLEIC ACIDS. | AMGEN (US) | 1987-10-19 | — | — | EP | disclosed |
| EP-0227795-A1 | METHOD FOR PERFORMING NUCLEIC ACID HYBRIDIZATION ASSAYS. | AMGEN (US) | 1987-07-08 | — | — | EP | disclosed |
| EP-0224578-A1 | COMPOSITIONS AND METHODS FOR FUNCTIONALIZING NUCLEIC ACIDS. | AMGEN (US) | 1987-06-10 | — | — | EP | disclosed |
| WO-1986007363-A1 | COMPOSITIONS AND METHODS FOR FUNCTIONALIZING NUCLEIC ACIDS | AMGEN (US) | 1986-12-18 | — | — | WO | disclosed |
| WO-1986007387-A1 | METHOD AND KIT FOR PERFORMING NUCLEIC ACID HYBRIDIZATION ASSAYS | AMGEN (US) | 1986-12-18 | — | — | WO | disclosed |